Stimulation of the c-Kit receptor tyrosine kinase has a critical role in the development and migration of melanocytes, and oncogenic c-Kit mutants contribute to the progression of some melanomas. c-Kit signalling activates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and their relative contribution to the activities of oncogenic and liganddependent c-Kit remains uncertain. We show that PI3K is a major regulator of MAPK activation in response to c-Kit activity and the dominant effector of c-Kit-driven melanocyte proliferation and melanoma survival. Nevertheless, inhibition of the PI3K pathway in c-Kit mutant melanoma cells did not replicate the apoptotic efficacy of the c-Kit inhibitor, imatinib mesylate. Instead, the simultaneous suppression of the PI3K and MAPK pathways promoted a strong synergistic apoptotic effect. These data indicate that MAPK functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Thus, the concurrent inhibition of PI3K and MAPK signalling is required to suppress oncogenic c-Kit activity and may provide an effective therapeutic strategy in c-Kit mutant melanomas.
INTRODUCTION
Signal transduction through the c-Kit receptor tyrosine kinase has a critical role in the differentiation, proliferation and migration of melanocytes. 1 Loss-of-function mutations in c-Kit or deficiencies in its ligand, stem-cell factor (SCF), lead to the depletion of melanocytes, failure of melanocytes to migrate to distant locations and hypopigmentation (reviewed in Roskoski 2 ). Gain-of-function mutations resulting in ligand-independent c-Kit kinase activity have been reported in over 80% of gastrointestinal stromal tumours (GISTs) and approximately 17% of T-cell lymphomas. 3 More recently, oncogenic c-Kit mutations and amplifications have been found in melanomas originating from mucosa, acral skin or skin with chronic sun-induced damage. [4] [5] [6] [7] Many of these mutations affect the juxtamembrane and proximal kinase regions of c-Kit, and this predicts responsiveness to targeted tyrosine kinase inhibitors such as imatinib mesylate. Clinical studies have confirmed that c-Kit is an important oncogene, with imatinib activity seen in patients with advanced GIST and in patients with c-Kit mutant metastatic melanoma. [8] [9] [10] [11] However, the median progression-free survival for patients with c-Kit mutant melanomas treated with imatinib is o4 months, 11, 12 and acquired resistance, while not yet comprehensively studied in melanoma, often involves the re-activation of c-Kit in GIST via secondary mutations and genomic amplification. 13 Furthermore, many primary activating c-Kit mutations are insensitive to imatinib inhibition. 11 Many reports, including studies using melanocytes, have demonstrated that ligand-induced activation of the c-Kit receptor promotes signalling via the phosphatidylinositol 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathways. [14] [15] [16] [17] [18] What remains unclear, however, is the relative contribution of the MAPK and PI3K cascades to c-Kit activity 15, [17] [18] [19] and whether oncogenic c-Kit mutants alter the fidelity of wild-type c-Kit signalling. Defining the key effectors of oncogenic c-Kit activity is clinically relevant considering that inhibitors of the MAPK pathway show activity in patients with MAPK-activated melanoma 20 and that PI3K blockade shows strong synergy with MAPK inhibition in melanoma cells with enhanced receptor tyrosine kinase (PDGFRb (platelet-derived growth factor receptor b) and IGF-1R (insulin-like growth factor-1 receptor)) signalling. 21, 22 In this report, we compared the contribution of the MAPK and PI3K pathways in ligand-dependent and oncogenic c-Kit signalling. We focussed on cell proliferation and tumour cell survival, characteristics that are intimately involved in cell transformation. We report that both MAPK and PI3K pathways were rapidly and potently activated by ligand-dependent and oncogenic c-Kit signalling and that stimulation of PI3K was required for full MAPK activity. Accordingly, the PI3K pathway was the primary effector of ligand dependent c-Kit-induced melanocyte proliferation and co-operated with MAPK signalling to regulate oncogenic c-Kit-driven melanoma proliferation and survival. Notably, melanoma cell lines expressing mutant c-Kit were insensitive to MAPK pathway inhibition, showed diminished viability in response to PI3K suppression and markedly increased cell death when MAPK and PI3K signalling were simultaneously inhibited. The concurrent inhibition of MAPK and PI3K signalling also induced potent synergistic cell death in melanoma cells with acquired resistance to imatinib mesylate. These data indicate that oncogenic c-Kit utilises MAPK as a redundant survival pathway that reinforces PI3K signalling in melanoma. 1 Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia and RESULTS Activated PI3K stimulates MAPK signalling and proliferation in response to ligand-activated wild-type c-Kit The downstream effects of ligand-dependent c-Kit activation were evaluated in primary human neonatal melanocytes (HEM1455, HEM1259), and the results for the HEM1455 cells are depicted in detail. Cells were exposed to 10 ng/ml SCF over a 72-h time course. This dose of SCF induced optimal levels of activated c-Kit (data not shown), and melanocytes responded by phosphorylating c-Kit in a rapid but transient manner with levels of total and phosphorylated c-Kit (p-c-Kit) diminishing within 30 min of SCF treatment (Figure 1) .
The transient induction of c-Kit activity was closely associated with MAPK and PI3K pathway signalling. Elevated levels of p-ERK (phosphorylated extracellular signal-regulated kinase) and p-AKT were detected 10 min post-SCF addition and remained activated for the duration of these experiments (Figure 1 ). Established downstream MAPK and PI3K targets such as the MITF (microphthalmia-associated transcription factor) transcription factor, ribosomal protein S6 and glycogen synthase kinase 3b (GSK-3b) also displayed rapid phosphorylation that was sustained only for the AKT effectors ( Figure 1 ). SCF induced melanocyte proliferation and stimulated the migration of melanocytes on collagen I (Figure 2 ).
The relative contribution and independence of the c-Kitinduced MAPK and PI3K pathways were analysed by exposing melanocytes to the MEK (MAPK) inhibitors, PD98059 or U0126 and to the PI3K inhibitors, wortmannin or LY294002. As shown in Figure 3 , MAPK inhibition suppressed SCF-induced ERK phosphorylation and led to the significant suppression of MITF phosphorylation. Importantly, AKT phosphorylation remained unchanged and was potently induced by SCF regardless of MAPK activity (Figure 3a) . Surprisingly, the inhibition of MAPK signalling did not alter the impact of SCF on the proliferation of epidermal melanocytes. Melanocyte proliferation as measured by bromodeoxyuridine (BrdU) incorporation, and Ki67 expression was induced by SCF irrespective of MAPK pathway activation (Figure 3b) . Similarly, inhibition of MAPK signalling did not alter the SCF-induced migration of melanocytes on collagen I; that is, melanocyte migration was increased by SCF in the absence of MAPK pathway activation (Figure 3b ).
The application of PI3K inhibitors 1 h before SCF treatment led to a decrease in the SCF-induced phosphorylation of AKT, with wortmannin particularly effective at the early 1 h time point (Figure 4a ). The suppression of AKT was associated with the inhibited phosphorylation of downstream effectors GSK-3b and ribosomal protein S6 (Figure 4a ). Importantly, ERK phosphorylation was reproducibly dampened by PI3K inhibition both at early and late time points post-SCF addition, demonstrating that SCFinduced MAPK activation was dependent, at least in part, on the PI3K signalling network (Figure 4a ). Analysis of SCF-induced melanocyte proliferation and migration revealed that both required active PI3K signalling, and increased melanocyte proliferation in response to SCF was abolished by both PI3K inhibitors (Figure 4b) . Similarly, inhibition of PI3K signalling using LY294002 abolished the increased migration induced by SCF (Figure 4b ). (Figure 5a ). c-Kit inhibition induced proliferative arrest and apoptosis in both these c-Kit mutant melanoma lines ( Figure 5b ). As previously reported, the WM3211 cell line did not respond to imatinib mesylate, 27 and additional analyses revealed that these cells do not accumulate detectable levels of c-Kit and show no evidence of c-Kit activation ( Figure 5a ). As a result, c-Kit signalling was not explored in the WM3211 cell line.
To determine the contribution of c-Kit induced MAPK and PI3K pathways in melanoma, we exposed MelMS and M230 cells to the MEK (MAPK) inhibitors, U0126 or AZD6244, and to the PI3K inhibitors, LY294002 or BEZ235. The newer generation and more potent AZD6244 and BEZ235 inhibitors (BEZ235 inhibits PI3K and mTOR (mammalian target of rapamycin)) replaced PD98059 and wortmannin in these later studies. In both the cell lines, the inhibition of MAPK signalling diminished the ligand-independent phosphorylation of ERK ( When the MelMS and M230 cells were exposed to the PI3K inhibitors, LY294002 or BEZ235, they showed reduced phosphorylation of AKT and diminished activation of the AKT targets, S6 and GSK-3b ( Figure 6a ). In addition, as was the case in human melanocytes with ligand-activated c-Kit (Figure 4a ), the inhibition of PI3K significantly dampened p-ERK signalling in the c-Kit mutant melanoma cells. Moreover, both melanoma cell lines were sensitive to the PI3K inhibitors and showed diminished proliferation and viability, with significant levels of early apoptosis (Figures 6b and c, Supplementary Figure S1 ).
The central role of the PI3K network in c-Kit dependent melanocytes and melanomas may reflect the fact that PI3K Figure 1 . Ligand dependent c-Kit stimulation activates MAPK and PI3K signalling. Human melanocytes were left untreated ( À ) or treated with 10 ng/ml SCF ( þ ) for increasing duration. The accumulation and phosphorylation of c-Kit, and components of the MAPK and PI3K cascades were determined by immunoblotting.
c-Kit signalling in human melanocytes and melanoma JR Todd et al signalling, as measured by phosphorylated AKT, was high in these cells. In particular, primary melanocytes and melanoma cells with activated c-Kit displayed excessive p-AKT expression when compared with melanoma cells driven by oncogenic B-RAF or N-RAS (Figure 6d ). Only the V600E-positive NM39 and MM200 cells showed elevated p-AKT levels and this correlated with oncogenic BRAF and loss of PTEN. By contrast, MAPK signalling, as determined by p-ERK accumulation, was activated in all melanoma lines, irrespective of the oncogenic driving mutation. It is also worth noting that MAPK signalling, as measured by phosphorylation of ERK was significantly enhanced in the c-Kit mutant melanoma cells compared with melanocytes with ligand-stimulated SCF (Figure 6d ).
Simultaneous PI3K and MAPK inhibition leads to enhanced cytotoxicity in c-Kit-dependent and imatinib-resistant melanomas To investigate synergy between MAPK and PI3K inhibition in c-Kit mutant melanoma, we treated the MelMS and M230 cells with combinations of AZD6244 and BEZ235. Although both melanoma lines showed limited cytotoxic response to monotherapy, strong synergistic apoptosis was seen when AZD6244 was combined with BEZ235 (Table 1; Figure 6b ). AZD6244 and BEZ235 were used at concentration ratios of 4:1 and 1:1 for the M230 and MelMS cell lines, respectively and this reflected the different sensitivities of these cells to each drug (Figure 6c ). Concurrent treatment with MAPK and PI3K inhibitors caused more sustained and complete inhibition of AKT and ERK signalling, compared with either drug alone (Figure 7a ), providing a rationale for the observed synergy.
In particular, phosphorylation of the MAPK and PI3K downstream targets ERK and GSK-3b was more potently inhibited with the combination of AZD6244 and BEZ235, compared with either drug alone (Figure 7a ). Similar apoptosis synergy was observed when the MEK inhibitor U0126 was combined with the PI3K inhibitor, LY294002 (Supplementary Figure S1 , Supplementary Table S1 ).
To examine whether dual MAPK and PI3K inhibition could salvage imatinib-resistant melanoma cells, we derived three imatinib-resistant (IMR) M230 sublines by chronic exposure to 500 nM imatinib. A similar strategy failed to yield imatinib-resistant MelMS sublines. All M230-derived resistant lines (IMR22, IMR24, IMR25) retained the activating c-Kit L576P mutation (data not shown) and survived in the presence of imatinib (Figure 7b ). The resistant sublines did not show significant cytotoxic response to monotherapy, and although the potency of the AZD6244:-BEZ235 combination was variably reduced (Table 1) , all sublines showed strong synergistic apoptosis when exposed to AZD6244 in combination with BEZ235 (Table 1; Figure 7b ). Detailed examination of the most sensitive subline, IMR24, indicated that c-Kit signalling (that is, p-c-Kit accumulation) was retained in the presence of imatinib and that the apoptotic synergy induced by the AZD6244:BEZ235 drug combination was associated with strong PI3K and MAPK inhibition (Figure 7c ). melanomas. 5 Once activated, c-Kit regulates cell proliferation, migration and survival by transmitting signals to various pathways, including the MAPK and PI3K cascades. The activity and relative contribution of the MAPK and PI3K pathways in ligand-dependent and -independent c-Kit signalling remains unclear. For instance, immortalised, INK4a/ARF-depleted murine melanocytes responded to SCF and ectopically expressed mutant c-Kit by activating the PI3K, rather than the MAPK cascade. 19, 28 SCF also failed to activate MAPK activity in human melanoma cells expressing wild-type c-Kit. 19 By contrast, both PI3K and MAPK were potently activated by SCF in human epidermal and uveal melanocytes. 15, 18, 29 In human melanoma cells expressing endogenous mutant c-Kit, inhibition of c-Kit inhibited both the MAPK and PI3K cascades in the c-Kit V599A M6 cells but only suppressed PI3K signalling in the c-Kit S476I Ma-Mel 144al melanoma cells. 28, 30 Moreover, whereas PI3K signalling was critical for ligand-dependent and -independent proliferation of human and murine melanocytes, 15 ,28 the constitutive c-Kit signalling in human melanocytes and melanoma JR Todd et al activation of the MAPK pathway was shown to be sufficient for SCF/c-Kit-controlled human melanoma cell proliferation. 17, 18 In this report, we conclusively demonstrate that both MAPK and PI3K cascades are potently activated in response to liganddependent and -independent c-Kit signalling in human melanocytes and melanoma cells. This is in line with a recent report confirming that human c-Kit mutant mucosal melanomas show activation of both the cascades. 31 We also report that the PI3K pathway is the dominant proliferative target of ligand-stimulated and mutant c-Kit. Further, although MAPK signalling did not contribute to the proliferation of SCF-stimulated melanocytes, it provided a significant, albeit ancillary proliferative and survival signal in c-Kit mutant melanoma cells. As a result, these melanoma cells did not require MAPK signalling for survival and were resistant to pharmacological inhibition of the MAPK pathway. This is in accordance with a recent study showing that c-Kit inhibition reduced the proliferation and survival of the Ma-Mel 144al c-Kit mutant melanoma cells, and this coincided with loss of PI3K signalling but retention of MAPK activity. 28 It is worth noting that, compared with the MelMS and M230 cell lines used in this study, the Ma-Mel 144al cells appear much less sensitive to imatinib mesylate, and it is possible that sensitivity to imatinib reflects the degree of PI3K and MAPK inhibition. Thus, the concurrent inhibition of MAPK and PI3K signalling induced strong synergistic melanoma cell death, confirming the critical but subordinate role of MAPK activity in melanomas carrying activating c-Kit mutations.
DISCUSSION
In our c-Kit dependent melanoma cell models, the inhibition of PI3K signalling consistently diminished the activity of the The simultaneous re-activation of the MAPK and PI3K pathways has been detected in imatinib-resistant GIST and melanomas 33, 34 c-Kit signalling in human melanocytes and melanoma JR Todd et al and also mediates some cases of melanoma resistance to MAPK inhibitors. 22, 35 Enhanced PI3K activation via the loss of PTEN, mutated N-RAS and overexpression of receptor tyrosine kinases (PDGFRb and IGF-1R) was detected in melanomas carrying oncogenic B-RAF V600E . 22, 35 These melanomas were refractory to single agents targeting the PI3K or MAPK cascades but were highly sensitive to the combined inhibition of the MAPK and PI3K/ mTOR pathways. 21, 36, 37 Thus, combination therapy, independently targeting both the MAPK and PI3K/mTOR survival networks may prove generally translatable, and Phase I clinical trials of combined MAPK/PI3K inhibition are under way (ClinicalTrials.gov). 38 Our data provide a rationale for the concurrent inhibition of the MAPK and PI3K/mTOR pathways in imatinib-resistant cancers. Certainly, preclinical studies indicate that combinations of imatinib and PI3K inhibitors co-operate in promoting apoptosis in imatinib-resistant GIST, 33 and the simultaneous inhibition of c-Kit and MAPK signalling supressed the proliferation of imatinib-resistant pancreatic cells. 39 These data reinforce the notion that targeting multiple downstream effector pathways may provide a generalised and sustained clinical response that may complement the inhibition of single driver oncogenes, such as mutant c-Kit or B-RAF. 
40
) MelMS and MelRMu cells were kindly provided by Professor P. Hersey. Unless otherwise specified, melanoma cells were grown in Dulbecco's modified Eagle's medium (GIBCO BRL) supplemented with 10% FCS, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and glutamine. M230 cells were kindly provided by Prof A. Ribas and grown in RPMI-1640 medium (Lonza, Walkersville, MD, USA) supplemented with 10% FCS, HEPES and glutamine. M230-resistant sublines were additionally maintained in 500 nM imatinib. WM3211 cells were kindly provided by Meenhard Herlyn and grown in RPMI-1640 as above. All cells were cultured in a 37 1C incubator with 5% CO 2 .
Treatment of melanocytes
Early passage number melanocytes (passages 7-8) were seeded onto flasks or plates in SCF-free media and allowed to adhere for 48 h before treatment. Media was removed at the 0 h time point. SCF (R&D Systems, Minneapolis, MN, USA) was added where appropriate to this media, and the original media was replaced on the cells. For longer experiments, fresh media was added at the 0 h time point to ensure no media was used for longer than 3 days. MAPK and PI3K inhibitors U0126, PD98059, wortmannin and LY294002 were obtained from Cell Signalling (Danvers, MA, USA); AZD6244, BEZ235 and imatinib mesylate were obtained from Selleck Chemicals (Houston, TX, USA).
Western blotting
Total cellular proteins were extracted at 4 1C using the RIPA lysis buffer containing protease inhibitors (Roche, Basel, Switzerland) and phosphatase inhibitors (Roche). Total proteins (40 mg) were resolved on 12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). Western blots were probed with the following antibodies. 
Indirect immunofluorescence
Cells were seeded onto coverslips in 6-well plates at 6E 4 cells per well. Cells were washed in phosphate-buffered saline (PBS) and fixed with 4% formaldehyde/PBS for 15 min at room temperature. Cells were rinsed three times with PBS, permeabilized with 0.2% Triton X-100/PBS for 10 min, then rinsed and blocked in 10% FCS/PBS for 1 h. For BrdU staining, the cells were pulsed with BrdU (Amersham Biosciences, Piscataway, NJ, USA) for either 16 h (HEM1455) or 8 h (MelMS, M230) before fixation as detailed above and then treated for 20 min with approximately 7U RQ1 DNase (Promega, Madison, WI, USA). Cells were incubated with primary antibodies for 50 min, washed then incubated with Alexa Fluor 594-conjugated secondary IgG (Molecular Probes, Carlsbad, CA, USA) and 1 mg/ml of the nuclear DNA stain 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for 50 min. Primary antibodies used were Ki67 (MIB-1; DAKO) and BrdU (BU-1; Amersham Biosciences, Piscataway, NJ, USA).
Cell migration HEM1455 cells were plated at 6E 4 cells/well onto 24-well plates coated with 300 mg/ml bovine Collagen I (Trevigen, Gaithersburg, MD, USA). After 24 h, media was replaced with fresh media containing DMSO (dimethyl sulphoxide), U0126 or LY294002. After a further 1 h, wounds were made with the Essen WoundMaker tool (Essen Instruments, Ann Arbor, MI, USA), wells were washed with media and media replaced with fresh media containing the above drugs in addition to 10 ng/ml SCF as appropriate. Cells were placed in the Incucyte system (Essen Instruments) at 37 1C and 5% CO 2 , and wound closing was monitored automatically at 2 h intervals. Density was calculated using the Relative Wound Density algorithm in the Incucyte software as the percentage of density of the wound compared with that of surrounding cells.
Pharmacological growth inhibition assays
Cultured cells were seeded into 96-well plates (1-2 E 3 cells per well) and 24 h after seeding, serial dilutions of the relevant compound prepared in media were added to cells. Cells were incubated for 72 h following addition of drug. Cell viability was measured using the Cell proliferation Aqueous MTS assay (Promega) on a VICTOR 2 Multilabel counter (Perkin Elmer, Waltham, MA, USA). Viability was calculated as a percentage of control (untreated cells) after background (no cells) subtraction. A minimum of two independent viability assays each performed in triplicate was carried out for each cell line and drug combination. IC 50 data were generated from dose-response curves fitted using a four-parameter regression fit in GraphPad PRISM 5 software (GraphPad, San Diego, CA, USA).
Apoptosis analysis
Adherent and floating cells were combined and apoptosis was analysed by Annexin V. Annexin-V staining was performed as detailed by the manufacturer (BD Pharmingen, San Jose, CA, USA).
For combination drug studies, apoptosis was measured using Annexin-V staining as described above. The interaction between drugs was analysed by the Chou and Talalay median effect principle 41 using the Calcusyn programme (Biosoft, Ferguson, MO, USA). Synergy, additivity and antagonism are defined as combination index (CI)o1, ¼ 1 and 41, respectively. The effective dose (ED) is defined as the combined drug dose at which a defined percentage of cells are killed (that is, 90% of the cells are killed at ED90).
